<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5527631</article-id><article-id pub-id-type="pmcid-ver">PMC5527631.1</article-id><article-id pub-id-type="pmcaid">5527631</article-id><article-id pub-id-type="pmcaiid">5527631</article-id><article-id pub-id-type="pmid">28607017</article-id><article-id pub-id-type="doi">10.1128/AAC.00352-17</article-id><article-id pub-id-type="publisher-id">00352-17</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>High Accumulation and <italic toggle="yes">In Vivo</italic> Recycling of the New Antimalarial Albitiazolium Lead to Rapid Parasite Death</article-title><alt-title alt-title-type="running-head">Albitiazolium Pharmacodynamics in Murine Malaria</alt-title><alt-title alt-title-type="short-authors">Wein et al.</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wein</surname><given-names initials="S">Sharon</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taudon</surname><given-names initials="N">Nicolas</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maynadier</surname><given-names initials="M">Marjorie</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tran Van Ba</surname><given-names initials="C">Christophe</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Margout</surname><given-names initials="D">Delphine</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bordat</surname><given-names initials="Y">Yann</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fraisse</surname><given-names initials="L">Laurent</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wengelnik</surname><given-names initials="K">Kai</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cerdan</surname><given-names initials="R">Rachel</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bressolle-Gomeni</surname><given-names initials="F">Fran&#231;oise</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vial</surname><given-names initials="HJ">Henri J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Universit&#233; de Montpellier, Montpellier, France</aff><aff id="aff2"><label>b</label>Pharmacocin&#233;tique Clinique, Facult&#233; de Pharmacie, Universit&#233; de Montpellier, Montpellier, France</aff><aff id="aff3"><label>c</label>Sanofi Research &amp; Development, Marcy L'Etoile, France</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Sharon Wein, <email>sharon.wein-gratraud@umontpellier.fr</email>.</corresp><fn id="fn1" fn-type="present-address"><label>*</label><p>Present address: Nicolas Taudon, Unit&#233; de Toxicologie Analytique, Institut de Recherche Biom&#233;dicale des Arm&#233;es, Br&#233;tigny sur Orge, France; Fran&#231;oise Bressolle-Gomeni, R&amp;D Department, Pharmacometrica, Longcol, La Fouillade, France.</p></fn><fn fn-type="other"><p><bold>Citation</bold> Wein S, Taudon N, Maynadier M, Tran Van Ba C, Margout D, Bordat Y, Fraisse L, Wengelnik K, Cerdan R, Bressolle-Gomeni F, Vial HJ. 2017. High accumulation and <italic toggle="yes">in vivo</italic> recycling of the new antimalarial albitiazolium lead to rapid parasite death. Antimicrob Agents Chemother 61:e00352-17. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.00352-17">https://doi.org/10.1128/AAC.00352-17</ext-link>.</p></fn></author-notes><pub-date pub-type="epreprint"><day>12</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2017</year></pub-date><volume>61</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">295903</issue-id><elocation-id>e00352-17</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2017</year></date><date date-type="rev-request"><day>27</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>01</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>25</day><month>01</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-05 23:25:09.413"><day>05</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2017 American Society for Microbiology.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Society for Microbiology</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="asm" xlink:href="https://doi.org/10.1128/ASMCopyrightv1"><license-p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/ASMCopyrightv1">All Rights Reserved</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="e00352-17.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="zac008176444001.pdf"/><abstract><title>ABSTRACT</title><p>Albitiazolium is the lead compound of bisthiazolium choline analogues and exerts powerful <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> antimalarial activities. Here we provide new insight into the fate of albitiazolium <italic toggle="yes">in vivo</italic> in mice and how it exerts its pharmacological activity. We show that the drug exhibits rapid and potent activity and has very favorable pharmacokinetic and pharmacodynamic properties. Pharmacokinetic studies in <named-content content-type="genus-species">Plasmodium vinckei</named-content>-infected mice indicated that albitiazolium rapidly and specifically accumulates to a great extent (cellular accumulation ratio, &gt;150) in infected erythrocytes. Unexpectedly, plasma concentrations and the area under concentration-time curves increased by 15% and 69% when mice were infected at 0.9% and 8.9% parasitemia, respectively. Albitiazolium that had accumulated in infected erythrocytes and in the spleen was released into the plasma, where it was then available for another round of pharmacological activity. This recycling of the accumulated drug, after the rupture of the infected erythrocytes, likely extends its pharmacological effect. We also established a new viability assay in the <named-content content-type="genus-species">P. vinckei</named-content>-infected mouse model to discriminate between fast- and slow-acting antimalarials. We found that albitiazolium impaired parasite viability in less than 6 and 3 h at the ring and late stages, respectively, while parasite morphology was affected more belatedly. This highlights that viability and morphology are two parameters that can be differentially affected by a drug treatment, an element that should be taken into account when screening new antimalarial drugs.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>antimalarial activity</kwd><kwd>antimalarial agents</kwd><kwd>malaria</kwd><kwd>pharmacodynamics</kwd><kwd>pharmacokinetics</kwd><kwd>pharmacology</kwd></kwd-group><funding-group><award-group id="award1"><funding-source id="gs1">Pole of competitiveness EuroBioMed</funding-source><award-id rid="gs1">InnoMAD</award-id><principal-award-recipient>Henri J. Vial</principal-award-recipient></award-group><award-group id="award2"><funding-source id="gs2">European Commission (EC)
<named-content content-type="funder-id">https://doi.org/10.13039/501100000780</named-content></funding-source><award-id rid="gs2">LSHP-CT-2005-018834</award-id><award-id rid="gs2">FP7/2007-2013</award-id><award-id rid="gs2">242095</award-id><principal-award-recipient>Henri J. Vial</principal-award-recipient></award-group><award-group id="award3"><funding-source id="gs3">Sanofi
<named-content content-type="funder-id">https://doi.org/10.13039/100004339</named-content></funding-source><principal-award-recipient>Henri J. Vial</principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><fig-count count="7"/><table-count count="3"/><equation-count count="0"/><ref-count count="27"/><page-count count="17"/><word-count count="10845"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2017</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>